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Abstract: Farber disease (FD) is a rare lysosomal storage 
disorder resulting from acid ceramidase deficiency and 
subsequent ceramide accumulation. No treatments are 
clinically available and affected patients have a severely 
shortened lifespan. Due to the low incidence, the patho-
genesis of FD is still poorly understood. Here, we report a 
novel acid ceramidase mutant mouse model that enables 
the study of pathogenic mechanisms of FD and ceramide 
accumulation. Asah1tmEx1 mice were generated by dele-
tion of the acid ceramidase signal peptide sequence. The 
effects on lysosomal targeting and activity of the enzyme 
were assessed. Ceramide and sphingomyelin levels were 
quantified by liquid chromatography tandem-mass 
spectrometry (LC-MS/MS) and disease manifestations in 
several organ systems were analyzed by histology and 
biochemistry. We show that deletion of the signal pep-
tide sequence disrupts lysosomal targeting and enzyme 
activity, resulting in ceramide and sphingomyelin accu-
mulation. The affected mice fail to thrive and die early. 
Histiocytic infiltrations were observed in many tissues, 
as well as lung inflammation, liver fibrosis, muscu-
lar disease manifestations and mild kidney injury. Our 
new mouse model mirrors human FD and thus offers fur-
ther insights into the pathogenesis of this disease. In the 
future, it may also facilitate the development of urgently 
needed therapies.
Keywords: acid ceramidase; ceramide; Farber disease; 
lysosomal storage disorders.
Introduction
Farber disease (FD) is a rare lysosomal storage disorder 
resulting from acid ceramidase (human AC, murine Ac) 
deficiency (Sugita et al., 1972). AC is encoded by the ASAH1 
gene (murine Asah1), located on 8p21.3-p22 (Li et  al., 
1999). Functionally, AC is a lipid hydrolase and deacylates 
ceramide to sphingosine. Ceramide is an important lipid 
mediator and has been implicated in many pathologies, 
including apoptosis and inflammation (reviewed in Coant 
et al., 2017; Schuchman and Desnick, 2017). AC deficiency 
in FD results in an accumulation of lysosomal ceramide 
(Levade et al., 1995), which is considered the cause of the 
disease, although the molecular details are unknown.
FD clinically presents with deformed joints, sub-
cutaneous nodules and progressive hoarseness (Moser 
et al., 2001). It can resemble juvenile idiopathic arthritis 
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in infancy, for which it is commonly misdiagnosed at first 
(Kostik et  al., 2013; Sólyom et  al., 2014; Torcoletti et  al., 
2014). FD diagnosis is obtained by demonstration of 
reduced AC activity and/or abnormally high ceramide 
levels in cultured cells, biopsy samples or urine (Sugita 
et al., 1975; Dulaney et al., 1976; Fensom et al., 1979; Kudoh 
and Wenger, 1982; Antonarakis et  al., 1984; Ben-Yoseph 
et al., 1989; Levade et al., 1996). FD histology is character-
ized by granulomas with lipid-laden macrophages (Farber 
et  al., 1957). Depending on disease severity and organ 
involvement, seven subtypes have been classified (Moser 
et  al., 2001). Severely affected patients (subtype I and 
IV) rarely survive 2 years of age and exhibit lung involve-
ment (type I and IV), neurological deficits (type I) and/or 
hepatosplenomegaly (type IV). Patients with a less severe 
phenotype (type II–III, V–VII) may survive into adulthood. 
So far, the disease variability cannot be explained and 
the pathophysiology is still poorly understood. Several 
mutations in different domains of the enzyme have been 
described, including two single base pair mutations 
(Gln22His and His23Asp) in the signal peptide sequence 
(Zhang et al., 2000), but reports on genotype-phenotype 
correlations are missing for most of the identified ASAH1 
mutations.
Currently, no cure for FD exists and treatment options 
are limited to supportive care. Favorable results on joint 
manifestations have been reported in response to allo-
genic hematopoetic stem cell transplantation (Ehlert 
et al., 2006; Torcoletti et al., 2014) and AC enzyme replace-
ment therapy is currently being developed (He et al., 2017). 
Unfortunately, both options are unsuitable for patients 
with pulmonary disease and neurological involvement, 
which are hallmarks of severe FD (Yeager et al., 2000).
Apart from its role in FD, ceramide accumulation has 
also been attributed a pathogenic role in a number of other 
diseases, including for instance, respiratory diseases (i.e. 
cystic fibrosis; Teichgräber et al., 2008), neurological dis-
orders (i.e. major depression, Gulbins et  al., 2013, and 
neurodegeneration, Filippov et al., 2012), metabolic and 
cardiovascular disease (reviewed in Iqbal et al., 2017) and 
(auto-)inflammation [i.e. rheumatoid arthritis (Kosinska 
et al., 2014) and multiple sclerosis (Singh et al., 1998)].
We have generated an acid ceramidase mutant 
mouse model to mirror FD. Two further acid ceramidase 
loss-of-function models exist. The first deleted a large 
portion of the catalytic domain of acid ceramidase and 
was reported to be early embryonic lethal (Li et al., 2002). 
The second model is viable and carries a point-mutation 
(P361R) outside of the catalytic domain, which is puta-
tively involved in co-factor binding (Alayoubi et al., 2013). 
By studying disease manifestations in viable models of 
systemic Ac deficiency, new insights into the pathogen-
esis of FD and other ceramide-related diseases can be 
obtained.
Results
Deletion of acid ceramidase signal peptide 
disrupts lysosomal targeting and activity of 
acid ceramidase
We generated an Asah1 mutant mouse model by flanking 
Exon1, which encodes the enzyme’s signal peptide, with 
loxP sites and removed the neomycin selection cassette by 
crossing to Flp recombinant deleter mice. To generate the 
constitutive model, the floxed mice were mated with EIIa-
cre deleter mice and the resulting heterozygous offspring 
were subsequently mated among each other, result-
ing in Wt controls and homozygous Asah1tmEx1 mutants 
(Figure 1A).
To confirm the deletion of the signal peptide sequence 
on the RNA level, total RNA was isolated from several 
tissues, reverse transcribed and subjected to polymerase 
chain reaction (PCR) using a primer binding to the deleted 
sequence and a second primer bridging the Exon2/Exon3 
junction. Primers directed against the housekeeping 
protein RPS6 were used as positive controls. As expected, 
tissues obtained from  Asah1tmEx1 mice show no signal for 
the Asah1-Exon1 sequence (Figure 1B).
Deletion of Exon1 should result in either a complete 
knock-out phenotype due to the deletion of the start 
codon or lead to a mutant protein initiated from an alter-
native start codon. The later should lack lysosomal target-
ing because of the deletion of the signal peptide sequence. 
We studied this by analyzing the intracellular localization 
of Ac by confocal immunofluorescence analysis. Whereas 
Ac colocalized with the lysosomal marker protein Lamp1 
in Wt cells, no such colocalization was detected in cells 
derived from Asah1tmEx1 mutants (Figure 1C). Instead, Ac 
was distributed diffusely throughout the cytosol in these 
cells (Figure 1C).
We assessed the effect of disrupted lysosomal tar-
geting on Ac activity in a ceramidase activity assay. We 
used organ lysates from Asah1tmEx1 mice and NBD-labeled 
ceramide as the substrate and conducted the experiment 
at acidic pH. Asah1tmEx1 mutants exhibit reduced cerami-
dase activity in a tissue-specific manner, with significant 
reductions in ceramidase activity in liver, spleen, thymus 
and bone marrow (Figure 1D). Varying degrees of residual 
activity were observed in all organs (Figure 1D).
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Ceramide and sphingomyelin accumulate 
in Asah1tmEx1 mice
A key feature of FD is the accumulation of ceramide, 
which is thought to be the cause of the disease. We 
quantified ceramide levels in several tissues of Asah1tmEx1 
mice by liquid chromatography tandem-mass spectro-
metry (LC-MS/MS). Total ceramide was significantly ele-
vated in all tested  Asah1tmEx1 tissues. This also applied to 
each individual ceramide species tested (Figure 2A–F).
We also tested for potential changes upstream of cera-
mide by analyzing sphingomyelin levels. We observed an 
increase of C16- and C24:1-sphingomyelins in the lungs of 
Asah1tmEx1 mice, whereas C18-, C20-, C22-, and C24-sphin-
gomyelins were reduced (Figure 2G). In Asah1tmEx1 livers, all 
sphingomyelin species were significantly elevated except 
for C22- and C24-sphingomyelins (Figure 2H). Similarly, 
spleens of Asah1tmEx1 mice had elevated C16-, C22-, C24- and 
total sphingomyelin levels, but reduced C20-sphingomye-
lin (Figure 2I) and in Asah1tmEx1 kidneys, all sphingomyelin 
species were elevated except for C24- and C24-1  sphin-
gomyelin, which were reduced (Figure 2J). In Asah1tmEx1 
muscle and brain tissues, all sphingomyelin levels and 
total sphingomyelin were significantly increased without 
exception (Figure 2K, L).
Sphingosine, but not sphingosine-1-phos-
phate is elevated in Asah1tmEx1 mice
To test if the accumulation of ceramide impacts the 
activity of other sphingolipid-metabolizing enzymes, we 
quantified sphingomyelinase activity at acidic pH and 
ceramidase activity at neutral pH. Both were not signifi-
cantly altered in Asah1tmEx1 liver samples (Figure 3A, B). We 
also quantified sphingosine and sphingosine-1-phosphate 
(S1P) levels in the livers of Asah1tmEx1 mice. Liver sphingo-
sine levels showed a four-fold elevation in Asah1tmEx1 mice 
(Figure 3C), whereas S1P levels were not significantly dif-
ferent (Figure 3D).
Asah1tmEx1 mice fail to thrive, have severely 
shortened survival and show histopathologi-
cal signs of Farber disease
We tested the biological relevance of the increased cera-
mide and sphingomyelin levels in the Ac mutant mice 
by monitoring body weight and survival. Asah1tmEx1 mice 
weighed significantly less than their littermates already at 
the age of weaning, barely gained weight afterwards and 
started to lose weight from week 5 onwards (Figure 4A). 
The earliest death occurred on day 47 and no Asah1tmEx1 
mouse survived for more than 63 days (Figure 4B). No sig-
nificant differences were seen between male and female 
Asah1tmEx1 mice regarding weight changes and survival.
Figure 1: Deletion of acid ceramidase signal peptide disrupts lyso-
somal targeting and activity of acid ceramidase.
(A) The structure of the murine Asah1 gene in the Asah1fl/fl EIIa-cretg 
constitutive knock-out line is schematically shown. LoxP sites were 
added flanking Exon1. Upon EIIa-cre mediated excision Exon1 is 
deleted in the acid ceramidase mutant mice (Asah1tm1Ex1). Image 
adapted from Moser et al. (2001). (B) Total RNA was isolated from 
different tissues and reverse transcribed. The absence of Exon1 in 
Asah1tmEx1 mice was analyzed by PCR using a forward primer binding 
in the targeted region of Exon1. RPS6-PCR was conducted in parallel 
as a positive control. (C) Immunofluorescence staining of mesen-
chymal stem cells with antibodies directed against acid ceramidase 
(Ac, red) and the lysosomal marker lysosomal-associated membrane 
protein1 (Lamp1, green) to determine cellular localization of Ac in 
the knock-out model. Representative images of three independent 
experiments are shown. Scale bar: 10 μm. (D) Assessment of acid 
ceramidase activity upon deletion of the signal peptide. Organ 
lysates were prepared and incubated in the presence of NBD-labeled 
ceramide. Data are presented as mean ± SD (n = 4–7 mice for each 
group). Multiplicity adjusted p-values are indicated (two-way ANOVA 
with Bonferroni posttests): **p < 0.01; ***p < 0.001.
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Lysosomal storage diseases such as FD are char-
acterized by storage bodies (Sikora et  al., 2017). In 
electron-micrographs of liver and brain sections, we 
identified storage bodies of various shapes and sizes, 
the most prominent being lamellated, zebra-like bodies 
in hippocampal sections of the Asah1tmEx1 mutants 
(Figure 4C).
Clinically, the hallmark feature of FD is joint deforma-
tion. We analyzed knee joints of Asah1tmEx1 mice and noted 
marked synovial hyperplasia due to the presence of foamy 
Figure 2: Ceramide and sphingomyelin accumulation in Asah1tmEx1 mice.
(A–L) The effect of Asah1 knock-out on ceramide (A–F) and sphingomyelin (G–L) levels were analyzed by rapid resolution LC-MS/MS of  
snap-frozen organ samples of 6-week-old mice. Data are presented as mean ± SD (n = 10–13 mice for each group). Asterisks indicate  
significant differences of the respective lipid species compared to wildtype (Student’s t-test): *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 2 (continued)
macrophages (Figure 4D). No other arthritic markers, such 
as cartilage loss, bone erosion or exudation into the joint 
cavity were present (Figure 4D).
Granulomas with lipid-laden macrophages are gener-
ally considered a key feature of FD and these have been 
reported in several tissues. Asah1tmEx1 mice also showed 
such histiocytic infiltrations in the lymphoid organs, 
which even disrupted the underlying tissue architecture 
(Figure 4E).
Asah1tmEx1 share the characteristic inflamma-
tory cytokine profile of FD
Monocyte chemoattractant protein-1 (MCP-1) has been 
suggested to be the driver of macrophage infiltration in 
FD and a characteristic cytokine profile of FD patients has 
recently been published (Dworski et  al., 2017). To test if 
our mouse model matches this patient cytokine profile, 
we analyzed the serum levels of MCP-1, MIP-1 alpha, IL-6, 
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IL-12, VEGF and IP-10 in our mice. MCP-1, MIP-1α, VEGF 
and IP-10  were significantly elevated (Figure  5A–D), 
whereas IL-6 was not significantly different (Supplemen-
tary Figure 1) and IL-12 remained below the detection limit 
of the assay (not shown).
Macrophage accumulation in the central 
nervous system of Asah1tmEx1 mice
Severe FD typically presents with substantial neurological 
deficits. A recent publication using a mouse model for the 
disease has provided first insights into the central nervous 
system (CNS) component of the disease: lipid accumula-
tion due to acid ceramidase deficiency results in storage 
compounds in the CNS and an accumulation of microglia 
and/or macrophages, as well as some neurodegeneration 
late in the disease (Sikora et al., 2017). Given that we also 
observed storage compounds in the corpus callosum of 
our mice (Figure 4C), we further evaluated CNS disease 
manifestations. Luxol-fast blue-reation (LFP-PAS) indi-
cated no obvious demyelination, but showed focal infil-
tration of white matter tracts by ballooned macrophages 
(Figure  6A), containing cathepsin D-immunoreactive 
lysosomes (Figure 6B). These infiltrates were seen in the 
corpus callosum (Figure 6A), the subcortical white matter 
of the hemispheres, the corticospinal tract, the optic 
tract, the cerebellar white matter (Figure 6B), the pyrami-
dal tract and all spinal tracts. Perivascular macrophage 
cuffs were especially present in the cerebellum and in the 
meninges. Macrophage accumulation was also present in 
the olfactory bulb. Meninges showed a scattered, diffuse 
infiltration by monocytes/macrophages. Neurons of the 
first two cortical layers exhibited more intense cathepsin 
D-immunoreactivity compared to controls. The same was 
observed for plexus choroideus cells. The intraparenchy-
mal macrophage infiltrates were accompanied by astro-
glial activation, as demonstrated by glial acid fibrillary 
protein (GFAP) immunoreactivity (Figure 6C).
Hematological disease manifestations 
in Asah1tmEx1 mice
Some case reports have indicated hematological mani-
festations of FD (Antonarakis et al., 1984; Fujiwaki et al., 
1992; Mondal et al., 2009), but without any clear consist-
ency. We prepared blood counts to gain further insights 
and observed a significant reduction of leukocytes in 
Asah1tmEx1 mice (Figure  7A). Upon further differentiation, 
the number of circulating lymphocytes were reduced, 
whereas the numbers of granulocytes and monocytes 
remained unchanged (Figure 7B). The number of erythro-
cytes was significantly increased (Figure 7C). Whereas the 
mean corpuscular volume and the average mass of hemo-
globin in erythrocytes were significantly reduced (Figure 
7D–F), the total amount of hemoglobin did not change 
(Supplementary Figure 2A). The hematocrit and platelet 
counts were also normal (Supplementary Figure 2B, C).
Further, we determined weight and cellularity of 
immune organs relative to the body weight. We performed 
these and all subsequent hematological analyses with 
35-day-old mice, which represents a time-point shortly 
before the Asah1tmEx1 start to manifest signs of severe disease. 
We found an enlargement of the spleen in Asah1tmEx1 mice, 
while the absolute number of splenocytes was reduced 
(Figure 7G). The size of the thymus was unchanged, but 
Figure 3: Sphingosine, but not sphingosine-1-phosphate increases 
in Asah1tmEx1 mice.
(A, B) The effects of Asah1-Exon1 knock-out on the activity on 
sphingomyelinases was assessed at acidic pH (A), as well as 
the effect on the activity on other ceramidases at neutral pH (B). 
Lysates were prepared from livers and incubated in the pres-
ence of either BODIPY-labeled sphingomyelin (A) or NBD-labeled 
ceramide (B). Each sample was assessed in duplicate and the 
mean of each sample is plotted along with the group mean ± SD 
(n = 3–4 mice for each group). Student’s t-test showed no signifi-
cant differences compared to wildtype. (C, D) The effect of Asah1 
knock-out on sphingosine (C) and sphingosine-1-phosphate 
(S1P) (D) levels were analyzed by rapid resolution LC-MS/MS of 
snap-frozen organ samples of 42/43-day-old mice. Each replicate 
is presented including mean ± SD (n = 5 mice for each group). 
Asterisks indicate significant differences compared to wildtype 
(Student’s t-test): ***p < 0.001.
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thymus cellularity was significantly reduced in Asah1tmEx1 
mice (Figure 7G). A similar pattern was observed for lymph 
nodes (Figure 7G). In contrast, the bone marrow cellularity 
was not significantly altered (Figure 7G).
Histological analyses revealed that the enlargement 
of the spleen, lymph node and thymus was due to foamy 
macrophage infiltration, which disturbed the normal 
tissue architecture of the immune organs (Figure 4E). We 
further studied the cellular composition in these organs 
by flow cytometry. In addition to infiltration with mono-
cytic cells we also observed a significant infiltration with 
granulocytes (Figure 7H).
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Figure 4: Asah1tmEx1 mice fail to thrive, severely shortened survival and show histopathological signs of Farber disease.
(A, B) Mice were weighed once a week and the same mice were also monitored daily to assess survival (n = 13 at the starting point). (A) Body 
weight data are presented as mean ± SD Asterisks indicate significant differences compared to the wildtype (Wt) group at the indicated time 
point (repeated measures ANOVA with Bonferroni posttests): ***p < 0.001. (B) Differences in survival were assessed using the log-rank/
Mantel-Cox test and the resulting p-values are indicated. The survival of male and female Asah1tmEx1 was not significantly different. (C) Elec-
tron micrographs of thin sections through the hippocampi of 6-week-old Wt (left) and Asah1tmEx1 mice (right). Zebra-like storage bodies (red 
circles) lie between myelinated and unmyelinated fibers. Scale bar: 1 μm. (D, E) histopathology of the effects of ceramide and sphingomyelin 
accumulation in 6-week-old mice. (D) SafraninO/FastGreen staining and (E) hematoxylin/eosin staining of perfused, paraformaldehyde-
fixed and paraffin-embedded tissue sections. Red arrows indicate foamy macrophage infiltration. Representative images of n ≥ 6 mice are 
shown for each group. Scale bar: 50 μm.
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We also performed more detailed analyses of the lym-
phocyte subsets in the blood and thymus, as well as of 
bone marrow progenitor cells. Both B- and T-lymphocytes 
were significantly decreased in the peripheral blood of 
Asah1tmEx1 mice (Figure 7J). In the thymus, CD4/CD8 double 
positive T cells were also markedly reduced, resulting in 
a marked decrease of CD4 and CD8 single positive T cells 
as well (Figure 7K). The CD4/CD8 double negative popula-
tion remained unchanged (Figure 7K).
Analysis of the bone marrow revealed an expansion of 
the early hematopoietic stem and progenitor cell compart-
ment [lineage negative, Sca1 positive, c-kit positive (LSK) 
cells] and the lineage committed progenitor cell compart-
ment (c-kit single positive cells), whereas the long-term stem 
cells (LT-HSC) were unaffected (Figure 7K). The increase in 
the early progenitor cell compartment did not result in higher 
blood cell counts (Figure 7A, B, Supplementary Figure 2C).
Lung inflammation in Asah1tmEx1 mice
Pulmonary involvement has been reported for all severely 
affected FD patients and over half of the patients for whom 
a cause of death has been reported have died of pulmo-
nary complications. Additionally, ceramide accumula-
tion is also associated with lung inflammation, cell death 
and infection susceptibility in cystic fibrosis (Teichgräber 
et al., 2008). Lung sections of Asah1tmEx1 mice show lung 
infiltration (Figure 8A), which was subsequently quanti-
fied as a significant increase in cell numbers per lung 
by flow cytometry (Figure 8B). Further characterization 
showed that this was due to neutrophil infiltration (Figure 
8C). Myeloid-derived suppressor cells (MDSCs) were also 
elevated, but macrophage numbers were not altered 
(Figure 8C). Dendritic cell- and B-cell numbers decreased 
significantly (Figure 8D, E), while T cell numbers also 
remained unaltered (Figure 8F).
Figure 5: Asah1tmEx1 share the characteristic inflammatory cytokine 
profile of FD.
(A–D) Serum cytokine levels were quantified by enzyme-linked 
immunosorbent assay (ELISA) on day 40–44. Each replicate is 
presented as well as mean ± SD. Asterisks indicate significant 
differences as assess by Student’s t-test: *p < 0.05; **p < 0.01; 
***p < 0.001. No significant differences were observed for IL-6 
(Supplementary Figure 1) and levels of IL-12 remained below the 
detection limit.
Figure 6: Central nervous system involvement in Asah1tmEx1 mice.
(A–C) Paraformaldehyde-fixed and paraffin-embedded brain sec-
tions of 5-week-old mice were stained with luxol-fast blue (LFP-PAS) 
(A), Cathepsin D (B) or glial acid fibrillary protein (GFAP) (C). Repre-
sentative images of corpus callosum (A + C) and cerebellum (B) are 
shown for each group. Scale bar: 100 μm.
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Figure 7: Hematological disease manifestations in Asah1tmEx1 mice. 
(A–F) Hematological manifestations of Farber disease were assessed in 5–6-week-old mice by blood counts in EDTA-anti-coagulated blood 
using a VetABC™ (Scil). Each replicate is presented including mean ± SD (B). Indicated p-values are the result of Student’s t-test: *p < 0.05; 
**p < 0.01; ***p < 0.001. No significant differences were observed for hemoglobin, hematocrit and platelets (see Supplementary Figure 
2A–C). (G) Organs of 35-day-old mice were resected and weight. Single cell suspensions were prepared and cell numbers determined on a 
Z2 cell counter (BD, Krefeld, Germany). To correct for the pronounced differences in body weight between the two groups, organ weights 
are displayed as the ratio of organ weight to body weight and cell counts are displayed as cells per bodyweight. Given are means ± SD of 
n = 4 mice per group. Indicated p-values are the result of Student’s t-test: *p < 0.05; **p < 0.01; ***p < 0.001. (H) Organs of 35-day-old mice 
were resected, single cell suspensions were prepared and lymphoid and erythroid cells were excluded via a lineage cocktail containing 
antibodies against CD3, CD4, CD8, TCRß, CD19, B220, Nk1.1 and Ter119. Granulocytes and monocytes were stained with antibodies directed 
against Mac-1 and Ly6G, respectively, and analyzed flow cytometrically. The percentage of mono- or granulocytes per total viable cells is 
reported. Given are means ± SD of n = 4 mice per group. Indicated p-values are the result of Student’s t-test: *p < 0.05; **p < 0.01; ***p < 0.001. 
(I) Blood was collected from 35-day-old mice by cardiac puncture and erythrocytes were lysed in NH4Cl hypotonic solution. Leukocytes were 
subsequently stained with antibodies directed against CD3 and CD19 and analyzed by flow cytometry. Each replicate is presented includ-
ing mean ± SD (n = 4 mice per group). Indicated p-values are the result of Student’s t-test: *p < 0.05; **p < 0.01; ***p < 0.001. (J) The thymi 
of 35-day-old mice were resected and single cell suspensions were prepared. T cells were stained with antibodies against CD4 and CD8 and 
analyzed by flow cytometry. Cell numbers are reported as number of cells per bodyweight. Given are means ± SD of n = 4 mice per group. Indi-
cated p-values are the result of Student’s t-test: *p < 0.05; **p < 0.01; ***p < 0.001. (K) Bone marrow was flushed from both femura of 35-day-
old mice and single cell suspensions were prepared and counted. To exclude mature hematopoetic cells from the analysis, a lineage cocktail 
with antibodies directed against CD3, CD4, CD8, TCRß, CD19, B220, Nk1.1, CD11b and Gr-1 was used. Hematopoetic stem- and early progenitor 
cells were then stained with antibodies against c-kit, Sca-1, CD48 and CD150. Cell numbers are reported as number of cells per bodyweight. 
Given are means ± SD of n = 4 mice per group. Indicated p-values are the result of Student’s t-test: *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 7 (continued)
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Asah1tmEx1 mice develop hepatic fibrosis
Hepatic manifestations have been reported in FD patients 
and ceramide has been linked to several liver diseases, 
including hepatic fibrosis (Quillin et al., 2015). Similar to 
the joints and lymphoid tissues, we observed foamy mac-
rophages in liver sections of Asah1tmEx1 mice (Figure  9A). 
This was found to be significant through scoring of 
the histiocytic infiltration by a blinded investigator 
(Figure  9B). Signs of early pericentral and pericellular 
fibrosis were also observed, which we confirmed through 
fibrosis staining (Figure 9C) and scoring (Figure 9D). We 
also analyzed clinical parameters that indicate hepatocel-
lular injury. Both glutamate-pyruvate transaminase (GPT) 
and glutamic-oxaloacetic transaminase (GOT) increased 
over time and were significantly elevated in 6-week-old 
Asah1tmEx1 mice (Figure 9E–F). Total serum protein and 
bilirubin levels, as well as albumin levels were not altered 
(Supplementary Figure 3C).
Muscular disease manifestations 
in Asah1tmEx1 mice
Despite reports that acid ceramidase expression and 
activity are very low in skeletal muscle (Li et al., 1998), 
we observed a significant increase of ceramide in 
muscle tissue (Figure 2E). Upon observation, Asah1tmEx1 
mice showed some potential indicators of muscular dys-
trophy (progressive wasting, Figure 4A; scoliosis, wad-
dling gait). Additionally, mutations in the ASAH1 gene 
have also been reported in a subset of spinal muscular 
Figure 8: Lung inflammation in Asah1tmEx1 mice.
(A) Hematoxylin/eosin staining of perfused, paraformaldehyde-fixed and paraffin-embedded lung sections of 6-week-old mice. Representa-
tive images of n ≥ 6 mice are shown for each group. Scale bar: 50 μm. (B–F) The inflammatory infiltrate in the lung was quantified at 6 weeks 
and characterized by flow cytometry. (B) Absolute-, (C) myeloid-, (D) dendritic-, (E) T- and (F) B-cell numbers were quantified per lung in 
n = 4 mice. Indicated p-values are the result of Student’s t-test: *p < 0.05; **p < 0.01; ***p < 0.001.
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atrophy patients (Zhou et al., 2012; Dyment et al., 2014; 
Gan et al., 2015; Filosto et al., 2016). This prompted us to 
check for muscular manifestations of ceramide accumu-
lation in the Asah1tmEx1 mice. Histopathological analysis 
showed centrally displaced nuclei and some atrophic 
fibers in 6-week-old Asah1tmEx1 mice, which would be 
consistent with neurogenic atrophy (Figure  10A). We 
also measured creatinine phosphokinase (CPK)- and 
lactate dehydrogenase (LDH) levels, two markers for 
tissue damage. CPK elevations, in particular, indicate 
damage to tissues with a high ATP-consumption (such 
as muscle tissue, kidney and brain) and frequently 
occur  in spinal muscular atrophy patients. Both CPK 
and LDH levels  increased significantly over time in 
Figure 9: Asah1tmEx1 mice develop liver fibrosis.
(A + C) Hematoxylin/eosin staining (A) and Masson-Trichrome staining (C) of perfused, paraformaldehyde-fixed and paraffin-embedded liver 
sections of 6-week-old mice. Representative images of n > 6 mice are shown for each group. Scale bar: 50 μm. (B + D) Histiocytic infiltration 
with foamy macrophages (B) and liver fibrosis (D) were scored on a scale of 0 (no signs) to 4 (very severe) by a blinded investigator. Each 
replicate is presented as well as mean ± SD. Indicated p-values are the result of Wilcoxon signed-rank test: *p < 0.05. (E-F) Liver parameters 
were determined in serum using a Spotchem™ (Scil). Each replicate is presented as well as mean ± SD. Multiplicity adjusted p-values are 
indicated (two-way ANOVA with Bonferroni posttests): ***p < 0.001. No significant differences were detected for total protein, total bilirubin 
and albumin (see Supplementary Figure 3A–C).
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Figure 10: Muscular manifestations in Asah1tmEx1 mice.
(A) Hematoxylin/eosin staining of paraformaldehyde-fixed and paraffin-embedded skeletal muscle (thigh) sections of 6-week-old mice. Rep-
resentative images of n > 5 mice are shown for each group. Scale bar: 50 μm. (B, C) Serum parameters were determined using a Spotchem™ 
(Scil). Each replicate is presented as well as mean ± SD. Multiplicity adjusted p-values are indicated (two-way ANOVA with Bonferroni post-
tests): ***p < 0.001.
Figure 11: Renal manifestations in Asah1tmEx1 mice.
(A) Hematoxylin/eosin staining of paraformaldehyde-fixed and paraffin-embedded kidney sections of 6-week-old mice. Representative 
images of n > 6 mice are shown for each group. Scale bar: 50 μm. (B) Serum creatinine was quantified in 6-week-old mice using a colorimet-
ric assay kit. Each replicate is presented as well as mean ± SD. No significant difference according to Student’s t-test. (C) Blood urea nitrogen 
was quantified using a Spotchem™ (Scil). Each replicate is presented as well as mean ± SD. Indicated p-values are the results of Student’s 
t-tests: ***p < 0.001.
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the Asah1tmEx1 mice, indicating damage to muscle cells 
(Figure 10B, C).
Renal manifestations in Asah1tmEx1 mice
Although kidneys are among the organs with the highest 
expression of AC (Li et al., 1999) and ceramide has been 
shown to accumulate in the kidneys of FD patients as well 
(Fujiwaki et al., 1995), little is known about kidney pathol-
ogies in FD. We observed no histological abnormalities in 
Asah1tmEx1 mice (Figure 11A), despite significant ceramide 
accumulation in Asah1tmEx1 kidneys (Figure 2D). Serum 
creatinine levels were unaltered in the mutants (Figure 
11B), although mutant mice weighed significantly less 
than their wildtype littermates (Figure 4A). Blood urea 
nitrogen, generally considered the stronger indicator of 
renal function, was significantly elevated in 6-week-old 
Asah1tmEx1 mice (Figure 11C), indicating a decrease of the 
glomerular filtration rate.
Discussion
FD is a severe genetic disorder with very limited treatment 
options. Pathophysiologically, little is known other than 
that ceramide accumulates due to mutations in the ASAH1 
gene. To gain further insights into the disease and to 
potentially enable the search for new treatment options, 
we have generated an Asah1 mutant mouse model through 
EIIa-cre mediated excision of Exon1 (Figure 1A). Two 
single base pair mutations (Gln22His and His23Asp) in 
Exon1  were previously identified in FD patients, but the 
clinical presentation of these patients was not described 
(Zhang et  al., 2000). Exon1 encodes the signal peptide 
and part of the α-unit. Our immunofluorescence analysis 
shows that rather than a complete knock-out phenotype 
due to deletion of the start codon, a mutant protein was 
initiated from an alternative start codon in our model. 
The mutant protein lacked lysosomal targeting due to the 
absence of the signal peptide (Figure 1C). Autocatalytic 
cleavage at acidic pH has been reported to be an impor-
tant requirement for Ac activation (Shtraizent et al., 2008). 
Consequently, we detected reduced Ac activities in all of 
the tested organs, which were statistically significant in 
the lymphoid organs and the liver – which were also pre-
dominantly affected by FD manifestations. The residual 
ceramidase activity measured with NBD-ceramide may in 
part be due to ceramide deacetylation by other enzymes, 
such as neutral and alkaline ceramidase 1-3, adiponectin 
receptors (Vasiliauskaite-Brooks et al., 2017) and N-acyle-
thanolamine acid amidase (Tsuboi et al., 2005). The latter 
enzyme even has high sequence similarity to AC. Further, 
the residual ceramidase activity in vitro may be due to the 
truncated, possibly active, mistargeted protein.
Our model appears to closely mimic the human 
disease and matches another mammalian model of FD – a 
mouse line with a point mutation in the Asah1 gene, puta-
tively at a site that is involved in the binding of saposin D 
(Alayoubi et al., 2013). An earlier attempt to knock-out the 
catalytic domain of Ac abrogated its activity completely 
and resulted in early embryonic lethality (Li et al., 2002). 
The authors subsequently showed that Ac expression 
was upregulated during embryonic genome activation, 
which was necessary to overcome the ceramide-mediated 
default apoptosis pathways normally initiated in unfer-
tilized oocytes (Eliyahu et  al., 2007). The residual Ac 
activity in our model is apparently sufficient to lower cer-
amide levels below this apoptotic threshold during early 
embryogenesis. Residual ceramide turnover has also been 
reported for FD patients (Levade et al., 1993).
Disrupted lysosomal targeting and Ac activity in our 
model resulted in ceramide accumulation as expected 
for FD (Figure 2A–F). The levels of many sphingomyelin 
species also increased (Figure 2G–L), but the activity 
of acid sphingomyelinase was not altered in an in vitro 
assay (Figure 3A). An increase in sphingomyelins is a new 
finding in FD, as the levels of other sphingolipids have not 
been analyzed in detail upon Ac deficiency yet. Only one 
study has suggested an increase in d18:2 and 24:1 sphingo-
myelin so far (Jones et al., 2014). Increased sphingomyelin 
levels may contribute to FD manifestations: Niemann-
Pick diseases type A and B, lysosomal storage disorders 
caused by acid sphingomyelinase deficiency and result-
ing in accumulation of sphingomyelin, share some fea-
tures with FD, including foam cell infiltration, pulmonary 
and hepatic involvement and central nervous symptoms 
(reviewed in Schuchman and Desnick, 2017).
We also noted an increase in sphingosine, but not S1P 
levels in the livers of Asah1tmEx1 mice. We chose to analyze 
livers, because they showed pronounced ceramide alter-
ations (Figure 2B) and pathologies of FD (Figure 9), but 
without the profound alterations of cellular composition 
seen in for instance the immune organs (Figure 7) or lungs 
(Figure 8). The sphingosine increase did not coincide with 
an increased ceramidase activity at neutral pH (Figure 3B), 
suggesting that it is not due to a compensatory effect on 
neutral ceramidase. Instead, sphingosine accumulation 
may be the result of enhanced activities of other enzymes 
with a ceramidase activity, i.e. adiponectin receptors, but 
further studies are necessary to elucidate which enzyme is 
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induced. In any case, the compensatory effect is limited, 
given that the approximately 50-fold increase in ceramide 
gives rise to only a four-fold increase in sphingosine.
Our Asah1tmEx1 mouse model mimicked many of the 
pathologies reported in FD patients: Mice failed to thrive 
(Figure 4A), survival was severely shortened (Figure 4B), 
storage bodies were detected by ultrastructural analysis 
(Figure 4C) and the characteristic foam cell infiltrations 
were present in several tissues, including the joints (Figure 
4D). We also report CNS, lung and liver involvement in our 
model (Figures 6, 8 and 9), which is typically present in 
the more severe forms of FD (Moser et al., 2001). Thus, our 
model seems to best fit FD subtype I and IV. Additionally, 
our mice also match the recently reported cytokine profile 
of FD patients (Figure 5) (Dworski et al., 2017).
Given the low incidence rate of FD, comprehen-
sive studies on FD manifestations are difficult and the 
pathophysiology of the disease is still largely unknown. 
Using our model, we have analyzed parameters that 
have previously been implicated in FD case reports, but 
without any clear consistency. Hematological analysis 
showed a reduction in blood lymphocytes (Figure 7A, 
B + J). Red blood cell numbers also increased (Figure 7C), 
but the erythrocyte indices were reduced (Figure 7D–F). 
Despite normal hemoglobin levels, these changes may be 
the consequence of an imbalance of cellular iron distribu-
tion in the context of chronic disease. A recent paper sug-
gests that elevations of erythrocytes in Farber mice may 
be due to poor respiration (Yu et al., 2018). Further studies 
are required to determine the exact mechanism. The 
observed leukopenia and normal hemoglobin levels at the 
first glance contrasts reports from the Asah1 point muta-
tion model, which reported significant elevations of leu-
kocytes in the peripheral blood and increased hemoglobin 
levels (Alayoubi et al., 2013; Yu et al., 2018). However, it is 
reasonable that this may reflect varying degrees of disease 
manifestations in the two models or analysis at different 
stages of the disease, considering that the point mutation 
model has a survival time of up to 91  days, whereas no 
Asah1tmEx1 mouse survived for more than 63 days.
We observed a marked reduction in lymphocyte counts 
in spleen, thymus and lymph nodes relative to the total body 
weight (Figure 7G). However, the relative organ weights 
were unchanged for lymph nodes and thymus and even 
increased for the spleen (Figure 7G). The lymphoid organs 
were largely infiltrated with granulocytes and monocytic 
cells (Figure 7H–I). CD4/CD8 double positive- and CD4 and 
CD8  single positive T cells (Figure 7K) were significantly 
decreased in the thymus. These findings indicate a severe 
defect in T cell maturation in our Farber model. A similar 
phenotype was also described for the point mutation model 
(Dworski et al., 2015). Dworski and colleagues also showed 
that this T cell maturation defect aggravates with time and 
coincides with foam cell infiltration in immune organs, sug-
gesting that the foam cells disrupt the niche for the devel-
opment of these cells (Dworski et al., 2017). Our findings are 
in line with these observations.
Similar to the Dworski study, we also observed an 
increase in immature and committed progenitor cells 
(Figure 7L). Despite the increase in progenitor cells in 
the bone marrow, however, the cellular blood counts 
(Figure  7A, B + J, Supplementary Figure 2C) were not 
increased. This could be due to an ineffective produc-
tion in the precursor cell compartment and/or due to an 
increased consumption of cells. Further experiments, 
which are beyond the scope of this article, are necessary 
to gain further insights.
Pulmonary complications are the leading docu-
mented cause of death among FD patients. Additionally, 
ceramide accumulation is known to cause cell death, 
infection susceptibility and inflammation in cystic fibrosis 
(Teichgräber et al., 2008). Both prompted us to investigate 
the lung phenotype of Asah1tmEx1 mice in more detail. The 
observed lung inflammation and particularly the neutro-
phil influx match reports from cystic fibrosis patients and 
also from the other Farber mouse model (Yu et al., 2018), 
confirming the pathogenic role of ceramide accumulation 
in these diseases.
Next to pulmonary complications, liver failure is a 
major concern in FD and hepatic failure occurs in up to 
25% of FD patients (Bao et al., 2017). Consistent with this, 
we report hepatocellular injury and liver fibrosis in our 
model. The later also matches reports from experimental 
models, indicating that ceramide mediates hepatic fibro-
sis (Quillin et al., 2015).
ASAH1 mutations have also been reported in a subset 
of spinal muscular atrophy patients (Zhou et  al., 2012; 
Dyment et al., 2014; Gan et al., 2015; Filosto et al., 2016). 
We observed some changes in our model that would be 
consistent with a moto-neuron disease, i.e. signs of neu-
rogenic muscular atrophy (Figure 10A), with biochemical 
signs of decay of muscular cells (Figure 10B–C) and pro-
gressive wasting (Figure 4A). However, further studies are 
necessary to elucidate this in more detail and to determine 
the definite cause of CPK elevations in our model, since we 
cannot exclude damage to other tissues (i.e. heart, brain, 
kidney) at this time. Nevertheless, our data indicates that 
the determination of CPK levels in FD patients may turn 
out to be a useful biomarker for FD. This would help to 
distinguish FD from juvenile idiopathic arthritis, a disease 
for which FD is commonly misdiagnosed (Sólyom et  al., 
2014; Torcoletti et al., 2014).
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So far, little is known about kidney pathologies in FD, 
which is somewhat surprising considering that kidneys 
have very high AC expression (Li et al., 1998). Despite the 
absence of histological abnormalities (Figure 11A), similar 
serum creatinine levels indicate renal injury when related 
to the body weight of the mice (Figure 11B), as do elevated 
blood urea nitrogen levels (Figure 11C). The late onset of 
these symptoms may indicate that they reflect secondary 
changes due to the chronic disease in Asah1tmEx1 mice.
Our model not only advances research into FD, but 
also enables insights into other diseases associated with 
ceramide accumulation. In the future, it may also facili-
tate the development of urgently needed therapies in 
these debilitating diseases.
Further, in our mouse model we flanked Exon-1 of the 
Asah1 gene with loxP sites. This allows us to generate tis-
sue-specific and inducible knock-outs of Exon1 and con-
sequentially specific deficiency of acid ceramidase. This 
may become a valuable tool in Farber disease research in 
the future and impact research into the role of acid cer-
amidase in various other mechanistic contexts.
Materials and methods
Animal husbandry
All mice were maintained on the C57BL/6-J background. Mice were 
bred and housed in the vivarium of the University Hospital Essen, 
Germany under pathogen-free conditions as defined by the Fed-
erations of European Laboratory Animal Science Associations 
(FELASA). Mice had ad libitum access to food and water and were 
kept on a 12 h/12 h light/dark cycle. Both male and female mice were 
used for analyses. Breeding of the mice was approved by the State 
Agency for Nature, Environment and Consumer Protection (LANUV) 
NRW in Düsseldorf, Germany.
Generation of the Asah1tmEx1 mouse model
A conditional Asah1 mutant model was generated by GenOway 
(Lyon, France) through flanking Exon1 with loxP sites and removal 
of the neomycin selection cassette via crossing to Flp recombinase 
deleter mice. In detail, the Asah1 cDNA sequence NM_019734  was 
used to establish the exon/intron organization of the Asah1 gene. On 
this basis, a targeting vector with two homology regions to the Asah1 
genomic sequence in the C57BL/6-J background (one of 5.8 kb and 
one of 1.7 kb), two loxP sites flanking Asah1 Exon1, a neomycin cas-
sette flanked by FRT sites and a diphtheria toxin A negative-selection 
marker was constructed. Upon homologous recombination of the 
targeting vector into C57BL/6 embryonic stem cells, the resulting chi-
meric mice were crossbred to C57BL/6 Flp deleter mice to remove the 
neomycin cassette. Resulting mice heterozygous for the Neo-excised 
conditional Asah1 mutant allele were crossed to a C57BL/6 EIIa-cre 
deleter line and the resulting offspring with the heterozygous excised 
allele was subsequently mated among each other to obtain homozy-
gous Asah1tmEx1 mutants and wildtype controls. Genotypes were rou-
tinely assessed by PCR using tail biopsies with the following primers:
1. 57447flp: ACAACTGTGTAGGATTCACGCATTCTCC;
2. 57448flp: TCGATCTATGAAATGTCGCTGTCGG;
3. 57445cre: CAGACTAATTCTACCACTTACTGTTCAGACCTC.
Primers 57447flp and 57448flp are combined to detect either the Wt 
allele (482 bp) or, if present, the floxed allele (585 bp). In a second 
PCR, primers 57448flp and 57445cre are combined to test for the exci-
sion of the floxed allele, yielding a 706 bp fragment if the allele was 
excised. Thus, Wt mice yield a 482 bp fragment in the first PCR, but 
no product in the second PCR, whereas Asah1tmEx1 show no product in 
the first PCR, but yield a 706 bp fragment in the second PCR.
To confirm the deletion of the signal peptide sequence on RNA 
level, total RNA was isolated from several tissues using the RNeasy 
Mini kit (Qiagen, Hilden, Germany) and transcribing the RNA to cDNA 
using the GoScript Reverse Transcription kit (Promega, Mannheim, 
Germany), both according to the manufacturer’s instructions. Subse-
quently, a PCR was conducted using a forward primer binding to the 
sequence encoding the signal peptide and a reverse primer bridging 
the Exon2/Exon3 junction, yielding a 220 bp fragment for the Wt allele 
or no fragment upon Cre-mediated excision in the Asah1tmEx1 samples. 
An additional primer pair directed against the housekeeping protein 
RPS6 was used as a positive control in the same reaction, generating a 
fragment of 246 bp. Primer sequences are as follows:
1. RPS6 fw: ATTCCTGGACTGACAGACAC;
2. RPS6 rev: GTTCTTCTTAGTGCGTTGCT,
3. Asah1 fw: GGGGCCAAAGTCTTCTCACC;
4. Asah1 rev: AAAATCCTCAACGCTGGTGCC.
Intracellular localization of Ac
Mesenchymal stem cells were generated as described before (Peis-
ter et al., 2004) and maintained in IMDM medium (Thermo Fischer 
Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine 
serum (GE Healthcare, Freiburg, Germany) and 10% horse serum 
(Thermo Fischer Scientific). Cells were seeded on coverslips and 
cultured to sub-confluency for 48 h. After washing and fixation with 
methanol, cells were blocked with 5% fetal bovine serum in permea-
bilization/washing solution (BD, Heidelberg, Germany) and subse-
quently incubated with an antibody directed against the β-unit of 
Ac (clone T-20, Santa Cruz Biotechnology, Dallas, TX, USA, 2 μg/ml), 
followed by addition of an antibody directed against the lysosomal 
marker protein Lamp1 (clone 1D4B, Abcam, Cambridge, UK, 1 μg/ml). 
After washing with permeabilization/washing solution (BD), cells 
were stained with Cy3-conjugated donkey-anti-goat IgG (#705-166-
147, 7.5 μg/ml) and AF647-conjugated-anti-rat IgG (#712-606-150, 7 μg/
ml; both Jackson ImmunoResearch, Suffolk, UK), washed, mounted 
with Mowiol (Hoechst, Frankfurt, Germany) and analyzed on a SP5 
confocal microscope (Leica microsystems, Wetzlar, Germany).
Determination of ceramidase and sphingomyelinase 
activity
Mice were sacrificed by CO2 exposure. Bone marrow was flushed 
from both femurs and tibias with PBS, pelleted by centrifugation and 
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snap-frozen. All other indicated organs were harvested, snap-frozen 
and pulverized under liquid nitrogen using a mortar and pestle. All 
samples were lysed in 250  mm sodium acetate, 1% NP-40 in a Tis-
sueLyser (Qiagen, Hilden, Germany) using 5 mm stainless steel beads 
(Qiagen) for 5 min at 50 Hz. An aliquot was removed and diluted to 
0.1% NP-40 for protein determination using the Bradford protein 
reagent (BioRad, München, Germany). The NBD-labeled ceramide- 
(Cayman Biochemical) or BODIPY-labeled sphingomyelin substrates 
(ThermoFisher Scientific) were dissolved in assay buffer (250  mm 
sodium acetate, 0.1% NP-40) and sonicated in an ultrasonic bath for 
10  min to induce micelle formation. Samples were sonicated sepa-
rately in parallel to the substrate. The substrate solution was then 
added to the samples to a final concentration of 180 pmol substrate/
sample in 250 mm sodium acetate, 0.1% NP-40 at either pH 4.5 (acid 
ceramidase activity), pH 5.0 (acid sphingomyelinase activity) or pH 
7.6 (neutral ceramidase activity). The reaction mixtures were incu-
bated for 1–2 h at 37°C with 300 rpm. The reaction was terminated 
by lipid extraction with chloroform:methanol (2:1, v/v). Phases were 
separated by centrifugation for 5  min at 15 000 g and the organic 
phase was collected dried in a SpeedVac at 37°C. Dried lipids were 
resuspended in chloroform:methanol (2:1, v/v) and spotted onto a 
thin layer chromatography plate (Macherey-Nagel, Düren, Germany). 
Thin layer chromatography was conducted with ethyl acetate:acetic 
acid (100:1, v/v, ceramidase assays) or chloroform:methanol (80:20, 
v/v, sphingomyelinase assays) as running buffer. The dried plates 
were imaged using a Typhoon FLA 9500 (GE) and spots were quanti-
fied with ImageQuant (GE Healthcare).
Ceramide and sphingomyelin quantification
Ceramides and sphingomyelin were extracted from indicated tissues 
and quantified as recently described (Huston et al., 2016). Briefly, lipid 
extraction was performed using C17-ceramide and C16-d31-sphin-
gomyelin as internal standards. Sample analysis was carried out by 
rapid-resolution LC-MS/MS using a Q-TOF 6530  mass spectrometer 
(Agilent Technologies, Waldbronn, Germany) operating in the posi-
tive ESI mode. The precursor ions of ceramides [C16-ceramide (m/z 
520.508), C17-ceramide (m/z 534.524), C18-ceramide (m/z 548.540), 
C20-ceramide (m/z 576.571), C22-ceramide (m/z 604.602), C24-cera-
mide (m/z 632.634) and C24:1-ceramide (m/z 630.618)] were cleaved 
into the fragment ion m/z 264.270. The precursor ions of sphingomy-
elin [C16-sphingomyelin (m/z 703.575), C16-d31-sphingomyelin (m/z 
734.762), C18-sphingomyelin (m/z 731.606), C20-sphingomyelin (m/z 
759.638), C22-sphingomyelin (m/z 787.669), C24-sphingomyelin (m/z 
815.700) and C24:1-sphingomyelin (m/z 813.684)] were cleaved into 
the fragment ion m/z 184.074. Quantification was performed with 
MassHunter Software (Agilent Technologies). Determined sphin-
golipid amounts were normalized to the actual protein content, as 
assessed by Bradford assay, of the tissue homogenate used for extrac-
tion.
Electron microscopy analysis
Samples were cut to tissue blocks of approx. 3–6  mm, fixed and 
processed for semi-thin sectioning and ultrastructural analysis by 
electron microscopy. All samples were fixed in 2.5% glutaraldehyde 
in sodium cacodylate buffer (pH 7.4) and embedded in epoxy resin 
as previously described (Zaugg et al., 1999). Ultrathin sections were 
viewed with a Philips CM 12 transmission electron microscope and 
micrographs obtained using a Morada camera (12 Megapixel) with 
AnalySIS ITEM software.
Histopathological assessment
Mice were sacrificed by CO2 exposure and perfused with 0.9% 
sodium chloride followed by 4% paraformaldehyde (PFA) via the 
right  ventricle. Organs were dissected and fixed further in 4% PFA, 
dehydrated with ethanol, embedded in paraffin and trimmed to 
4–6 μm thin sections (peripheral organs) or 1–5 μm thin sections 
(brain). These were stained as indicated with hematoxylin and eosin, 
SafraninO/FastGreen, Luxol blue/PAS or Masson Trichrome stain-
ing kit (Sigma-Aldrich, St Louis MO, USA). For immunhistochemi-
cal analyses, the following antibodies were used: polyclonal rabbit 
anti-GFAP (#Z0334, Dako, Glostrup, Denmark) and anti-Cathepsin D 
(#1029, R&D Systems, Minneapolis MN, USA). Slides were analyzed 
on a Leica SP5 (peripheral organs) or on an Olympus BX40 (brain). 
Histiocytic infiltration in various tissues and liver fibrosis were scored 
on a scale of 0 (no signs) to 4 (very severe) by a blinded investigator.
Cytokine analysis
Cytokine levels were quantified by enzyme-linked immunosorbent 
assay. Mice were sacrificed by CO2 exposure, blood was drawn from 
the V. cava inferior and serum was obtained by centrifugation at 2500 
g for 20 min. MCP-1, MIP-1, IL-6, IL-12 and VEGF levels were quantified 
using R&D Quantikine ELISA kits (R&D Systems, Minneapolis, MN, 
USA), CXCL1 levels by using the respective Abcam ELISA kit (Abcam, 
Cambridge, UK), according to manufacturer’s instructions.
Blood counts and clinical chemistry analysis
Blood was drawn and anti-coagulated with EDTA for blood counts 
using a VetABC™ (Scil). For differential blood counts, blood smears 
from the EDTA-anti-coagulated blood were prepared and two smears 
per mouse were counted manually.
Serum was obtained by centrifugation at 2500 g from coagu-
lated blood samples and analyzed using a SpotChem™ EZ chemistry 
analyzer with the corresponding parameter strips (Scil, Viernheim, 
Germany). When necessary, samples were diluted to enable measure-
ment of small sample volumes or when samples exceeded the maxi-
mum detection limit of a given parameter. Serum creatinine levels 
were quantified using a colorimetric assay kit (Cayman, Ann Arbor, 
USA).
Immune organ weights and cellularity
Spleen, thymus and inguinal lymph nodes were resected and 
weighed. For single cell suspension organs were passed through a 
70 μm cell strainer (BD, Heidelberg, Germany). Organ cellularity 
was determined on a Z2 cell counter (Beckmann Coulter, Krefeld, 
 Germany).
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Flow cytometry analysis of immune organs
Organs were dissected, single cell suspensions were prepared, 
stained with fluorochrome-conjugated antibodies and analyzed by 
flow cytometry on a LSRII flow cytometer (BD, Heidelberg, Germany). 
To distinguish mature hematopoietic cells from stem- and progenitor 
cells in the bone marrow, bone marrow cells were stained with a lin-
eage cocktail containing antibodies against the following antigens: 
CD3, CD4, CD8, TCRβ, CD19, B220, Nk1.1, CD11b and Gr-1. Hematopoi-
etic stem- and progenitor cells were stained with antibodies directed 
against c-kit, Sca-1, CD48 and CD150.
For the analysis of granulomonocytic cells, a lineage cocktail 
containing antibodies against CD3, CD4, CD8, TCRβ, CD19, B220, 
Nk1.1 and Ter119  was used to distinguish lymphoid and erythroid 
cells. Granulocytes and macrophages were stained with antibodies 
directed against CD11b and Ly6-G.
T-cells in the thymus we stained with anti-CD4 and anti-CD8 
antibodies.
Information regarding antibody concentrations, fluorochrome-
labels and manufacturers are summarized in Table 1.
Characterization of lung inflammatory infiltrate
Immune cell infiltration into the lung was characterized and quan-
tified by flow cytometry. Absolute cell counts were obtained from 
the live cell gate using forward- and sideward scatter. Specific cell 
types were defined as follows: Neutrophils: CD11b+, Ly6G+, F4/80-
; Macrophages: CD11b+, Ly6G-, F4/80+; MDSCs: CD11b+, Ly6G+, 
F4/80+; Dendritic cells: CD11c+, MHCII+; T-cells: CD3+; B-cells: B220+. 
The analysis was conducted on a FACS calibur (BD, Heidelberg, 
 Germany).
Information regarding antibody concentrations, fluorochrome-
labels and manufacturers are summarized in Table 2.
Statistical analyses
Data are presented as arithmetic means ± standard deviation. For 
two-group comparisons, we used Student’s t-test and for multiple 
comparisons we used analysis of variance (ANOVA) with Bonferroni 
posttests after confirming normal distribution with D’Agostino & 
Pearson omnibus normality test. Histopathological scores were com-
pared with the Wilcoxon signed-rank test and survival curves with 
the log-rank/Mantel-Cox test. All data were obtained from independ-
ent measurements.
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Table 1: Antibodies for flow cytometrical analysis.
Antigen Label Clone Supplier Concentration (μg/ml)
B220 PerCP-Cy5.5 RA3-6B2 BioLegend 2
CD11b PE-Cy7 M1/70 eBioscience 2
CD11b PerCP-Cy5.5 M1/70 BD Pharmingen 0.5
CD150 APC TC15-12F12.2 BioLegend 1
CD19 PerCP-Cy5.5 1D3 BD Pharmingen 4
CD3 PerCP-Cy5.5 145-2C11 eBioscience 2
CD4 PE-CY7 RM4-5 BD Pharmingen 1
CD4 PerCP-Cy5.5 RM4-5 BD Pharmingen 4
CD48 PE HM-48-1 BD Pharmingen 1
CD8 APC-Cy7 53-6.7 eBioscience 4
CD8 PerCP-Cy5.5 53-6.7 BioLegend 2
c-kit APC-Cy7 ACK2 eBioscience 4
Gr-1 PerCP-Cy5.5 RB6-8C5 BD Pharmingen 0.5
Ly-6G FITC 1A8 BD Pharmingen 5
Nk1.1 PerCP-Cy5.5 PK136 eBioscience 2
Sca-1 PE-Cy7 D7 BD Pharmingen 2
TCR beta PerCP-Cy5.5 H57-597 eBioscience 2
Ter119 PerCP-Cy5.5 TER119 eBioscience 2
Table 2: Antibodies for characterization of the lung inflammatory 
infiltrate.
Antigen   Label   Clone   Supplier   Concentration 
(μg/ml)
B220   FITC   RA3-6B2   BioLegend   0.5
CD11b   PE   M1/70   BioLegend   0.2
CD11c   PE   N418   eBioscience   0.5
CD3   PerCP-Cy5.5  145-2C11   eBioscience   2
Ly-6G   APC   1A8   BioLegend   0.2
F4/80   Alexa488   BM8   BioLegend   1
MHC-II   APC   AF6-120.1   eBioscience   0.2
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